📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
232 analysed today
FollowTelegram
232
Today
149,633
All-time analysed
42,906
Positive
6,661
Negative
91,389
Neutral
8,609
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
Jubilant Pharmova Re-appoints MD and Joint MD for 3-Year Terms Effective June 2026
The Board of Jubilant Pharmova has approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director. Both appointments are for a three-year duration starting June 1, 2026, pending shareholder approval. The leaders have been part of the board since 2017 and in their current executive roles since June 2023. This move ensures continuity in the company's strategic management and long-term vision.
Key Highlights
Re-appointment of Priyavrat Bhartia as MD for a 3-year term effective June 1, 2026.
Re-appointment of Arjun Shanker Bhartia as Joint MD for a 3-year term effective June 1, 2026.
Priyavrat Bhartia brings 29 years of industry experience with an MBA from Stanford University.
Arjun Shanker Bhartia is a Brown University graduate with prior strategy experience at Bain & Company.
👀 What to Watch
Investors should view this as a sign of management stability and continuity in strategic direction. No immediate action is required as these are expected re-appointments of the promoter-led management team.
Jubilant Pharmova Re-appoints MD and Joint MD for 3-Year Terms Effective June 2026
The Board of Jubilant Pharmova has approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director. Both appointments are for a further term of three years, starting June 1, 2026, and are subject to shareholder approval. Mr. Priyavrat Bhartia brings 29 years of industry experience, while Mr. Arjun Shanker Bhartia has a background in strategic consulting with Bain & Company. These re-appointments ensure leadership continuity within the promoter family, as both are sons of the Chairman and Co-Chairman respectively.
Key Highlights
Re-appointment of Mr. Priyavrat Bhartia as MD for a 3-year term effective June 1, 2026
Re-appointment of Mr. Arjun Shanker Bhartia as Joint MD for a 3-year term effective June 1, 2026
Mr. Priyavrat Bhartia has 29 years of industry experience and an MBA from Stanford University
Mr. Arjun Shanker Bhartia is a Brown University graduate with previous experience at Bain & Company
Both appointments are subject to the final approval of the company's shareholders
👀 What to Watch
Investors should view this as a move for leadership stability and continuity of the current strategic direction. No immediate action is required as this is a routine re-appointment of existing promoter-group leadership.
Jubilant Pharmova Recommends 500% Dividend of Rs 5 Per Share; Sets July 24 as Record Date
Jubilant Pharmova's Board has recommended a final dividend of Rs 5 per equity share for the financial year ended March 31, 2026, representing a 500% payout on its Re 1 face value. The company has officially fixed July 24, 2026, as the record date to determine shareholder eligibility for this payment. This announcement accompanied the release of the company's audited financial results, which received an unmodified opinion from statutory auditors Walker Chandiok & Co LLP. The dividend is subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of 500% amounting to Rs 5 per equity share of face value Re 1.
Fixed Friday, July 24, 2026, as the record date for the purpose of final dividend payment.
Approved audited standalone and consolidated financial results for the fiscal year ended March 31, 2026.
Statutory auditors issued an unmodified opinion, confirming the accuracy of the financial statements.
Dividend payment will be processed within 30 days from the date of the Annual General Meeting.
👀 What to Watch
Investors seeking dividend income should ensure they hold the shares before the July 24 record date to be eligible for the Rs 5 per share payout. The clean audit report further reinforces confidence in the company's reported financial performance.
Jubilant Pharmova Recommends Rs 5 Final Dividend; Sets Record Date for July 24, 2026
Jubilant Pharmova's Board of Directors has recommended a final dividend of Rs 5 per equity share for the financial year ended March 31, 2026, representing a 500% payout on the face value of Re 1. The company has officially fixed July 24, 2026, as the record date to determine shareholder eligibility for this payout. This announcement accompanied the approval of the company's audited financial results for FY26, which received an unmodified opinion from statutory auditors. The dividend remains subject to shareholder approval at the upcoming Annual General Meeting.
Key Highlights
Recommended a final dividend of Rs 5 per equity share (500% of face value)
Fixed July 24, 2026, as the record date for the purpose of dividend payment
Approved audited standalone and consolidated financial results for FY ended March 31, 2026
Statutory auditors Walker Chandiok & Co LLP issued an unmodified opinion on financial results
Dividend to be dispatched within 30 days from the date of the Annual General Meeting
👀 What to Watch
Investors seeking dividend yield should note the record date of July 24, 2026, to ensure eligibility. While the dividend is a positive signal of cash flow, investors should also review the detailed FY26 earnings for long-term growth prospects.
Jubilant Pharmova Re-appoints Priyavrat Bhartia as MD and Arjun Bhartia as Joint MD for 3 Years
The Board of Jubilant Pharmova has approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director for a further term of three years, effective June 1, 2026. Mr. Priyavrat Bhartia, aged 49, brings 29 years of industry experience and an MBA from Stanford, while Mr. Arjun Bhartia, aged 39, has a background in consulting with Bain & Company. These re-appointments ensure management continuity for the company's strategic operations. The appointments are subject to the final approval of the company's shareholders.
Key Highlights
Re-appointment of Mr. Priyavrat Bhartia as Managing Director for a 3-year term starting June 1, 2026
Re-appointment of Mr. Arjun Shanker Bhartia as Joint Managing Director for a 3-year term starting June 1, 2026
Mr. Priyavrat Bhartia possesses 29 years of industry experience and an MBA from Stanford University
Mr. Arjun Shanker Bhartia is a Brown University graduate with prior experience at Bain & Company
Both re-appointments are subject to the approval of the company's shareholders
👀 What to Watch
Investors should view this as a move for management stability and continuity. No immediate action is required as the leadership remains unchanged and aligned with the current long-term strategy.
Jubilant Pharmova's Montreal Facility Receives USFDA OAI Classification
Jubilant Pharmova's contract manufacturing facility in Montreal, Canada (CMO Montreal), has received an 'Official Action Indicated' (OAI) classification from the USFDA following an audit conducted in October and November 2025. An OAI status typically implies that the regulator may withhold approvals for new products from the site until issues are resolved. However, the company has already implemented remediation measures and resumed production operations at the facility in Q4'FY26. The company continues to work closely with the USFDA to address the specific audit observations.
Key Highlights
USFDA classifies CMO Montreal facility as Official Action Indicated (OAI) following late 2025 audit
Production operations at the site have successfully resumed in Q4'FY26 after remediation efforts
The facility is a strategic alliance under Jubilant HollisterStier, focusing on sterile injectables and ophthalmics
Jubilant Pharmova is working with the USFDA to resolve all outstanding regulatory observations
👀 What to Watch
Investors should monitor the timeline for the USFDA to upgrade the facility's status from OAI, as this classification can delay new product launches. While the resumption of production is a positive operational step, the regulatory risk remains until a successful re-inspection or close-out letter is received.
Jubilant Pharmova Q3 Revenue Rises 17% to Rs 2,123 Cr; CDMO Growth Offsets Montreal Shutdown
Jubilant Pharmova reported a solid 17% YoY revenue growth in Q3 FY26, reaching Rs 2,123 crore, driven by a 49% surge in the CDMO Sterile Injectables segment. However, normalized PAT declined by 17% to Rs 86 crore, and EBITDA margins contracted to 14.5% due to a temporary remediation-related shutdown at the Montreal facility. The company's leverage improved with Net Debt/EBITDA falling to 1.3x from 1.5x in the previous quarter. Management expects margin recovery in Q4 as production has resumed at the Montreal site and new capacities ramp up.
Key Highlights
Revenue grew 17% YoY to Rs 2,123 Cr, while 9M FY26 revenue reached Rs 5,990 Cr (up 13%).
CDMO Sterile Injectables revenue jumped 49% YoY to Rs 457 Cr, supported by the new Line 3 in Spokane.
EBITDA margins contracted by 172 bps YoY to 14.5% due to Montreal facility shutdown and remediation costs.
Ruby-Fill installation base grew by 37% in 9M FY26, significantly outpacing the 21% growth in FY25.
Generics business remained profitable for the third consecutive quarter with 13% revenue growth.
👀 What to Watch
Investors should focus on the margin recovery trajectory in Q4 as the Montreal facility resumes operations and high-margin Radiopharma products scale. The strong top-line growth in CDMO and Radiopharma provides a positive long-term outlook despite temporary operational headwinds.
Jubilant Pharmova Q3 Standalone Net Profit Rises 24.5% YoY to ₹66 Million
Jubilant Pharmova reported a 20% YoY growth in standalone revenue to ₹673 million for the quarter ended December 31, 2025. Profit before tax from continuing operations saw a significant surge of 90% YoY, reaching ₹101 million, primarily driven by a sharp reduction in finance costs. The company successfully completed the slump sale of its API business to its subsidiary, Jubilant Biosys, on September 1, 2025, which is now reflected as discontinued operations. Total net profit for the quarter stood at ₹66 million, up from ₹53 million in the corresponding quarter of the previous year.
Key Highlights
Standalone revenue from operations increased 20% YoY to ₹673 million in Q3 FY26.
Profit before tax from continuing operations surged 90% YoY to ₹101 million.
Finance costs significantly decreased to ₹9 million from ₹33 million in the year-ago period.
The API business transfer was completed for a net asset value of ₹5,956 million on September 1, 2025.
Total comprehensive income for the period stood at ₹67 million versus ₹51 million YoY.
👀 What to Watch
Investors should view the sharp reduction in finance costs and the restructuring of the API business as positive steps toward operational efficiency. Monitor the consolidated results for a clearer picture of the group's overall growth trajectory post-restructuring.
Jubilant Pharmova Q2 Standalone Revenue Up 8% YoY; Reports Net Loss of ₹64 Million
Jubilant Pharmova reported standalone revenue of ₹664 million for Q2 FY26, an 8% increase from ₹614 million in Q2 FY25. Despite revenue growth, the company posted a net loss of ₹64 million compared to a profit of ₹105 million in the previous year, primarily due to a significant deferred tax charge of ₹551 million. A major structural change was finalized during the quarter with the completion of the API business slump sale to its subsidiary, Jubilant Biosys, on September 1, 2025, which is now accounted for under discontinued operations.
Key Highlights
Standalone revenue from operations grew 8% YoY to ₹664 million in Q2 FY26.
Reported a net loss of ₹64 million for the quarter, heavily impacted by a ₹551 million deferred tax charge.
Profit from discontinued operations (API business) stood at ₹416 million for the quarter.
Completed the slump sale of the Active Pharmaceutical Ingredients (API) business to Jubilant Biosys Limited on September 1, 2025.
Total standalone assets decreased to ₹23,756 million from ₹29,096 million in March 2025 following the business transfer.
👀 What to Watch
Investors should focus on the consolidated financial performance rather than standalone figures, as the latter are significantly impacted by the internal restructuring and the divestment of the API business. Monitor how the reorganization into Jubilant Biosys affects overall group margins in the coming quarters.
Jubilant Pharmova appoints Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc.
Jubilant Pharmova Limited announced the appointment of Mr. Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc., a step-down subsidiary. Mr. O'Connor brings over 30 years of experience in Biotechnology and Oncology. He previously served as CEO of Ambrx Biopharma, where he drove a significant increase in company valuation leading to its acquisition. Jubilant Therapeutics is focused on developing innovative therapies across multiple cancer indications.
Key Highlights
Daniel J. O’Connor appointed as CEO of Jubilant Therapeutics Inc.
Daniel J. O’Connor has more than 30 years of leadership experience.
Jubilant Therapeutics Inc. is in Phase I/II clinical trial in multiple tumors with JBI-802.
👀 What to Watch
Investors should monitor the progress of Jubilant Therapeutics' clinical trials and any strategic collaborations. Keep an eye on how this leadership change impacts the development of new therapies.
Jubilant Pharmova appoints Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc.
Jubilant Pharmova Limited announced the appointment of Mr. Daniel J. O’Connor as CEO of Jubilant Therapeutics Inc., a step-down subsidiary. Mr. O'Connor brings over 30 years of experience in Biotechnology and Oncology. Previously, he served as CEO of Ambrx Biopharma, leading to a significant increase in company valuation and its subsequent acquisition. He also contributed to the development of a major oncology therapy at ImClone Systems. Jubilant Therapeutics is focused on developing innovative therapies across multiple cancer indications.
Key Highlights
Daniel J. O’Connor appointed as CEO of Jubilant Therapeutics Inc.
Daniel J. O’Connor has over 30 years of leadership experience in Biotechnology and Oncology.
Jubilant Therapeutics Inc. is a clinical stage biopharmaceutical company.
Jubilant Therapeutics Inc. is developing precision oral medicines for oncology and autoimmune diseases.
👀 What to Watch
Investors should monitor the performance of Jubilant Therapeutics under the new CEO, focusing on the progress of its clinical pipeline and strategic collaborations. Keep an eye on news related to JBI-802 and the novel brain-penetrant modulator of PRMT5.
